11 drugs likely to become blockbusters

Clarivate Analytics, a Philadelphia-based analytics company, released its annual Cortellis Drugs to Watch list Feb. 10.

The list includes 11 drugs that already have launched this year or are expected to launch this year and will likely become blockbusters by 2024. Blockbuster drugs are those that reach annual sales of $1 billion or higher.

Last year, only seven drugs were included in the list.

More than half of the drugs on this year's list are biologics and most are intended to be safer versions of existing drugs. 

The 11 drugs Clarivate expects to become blockbusters by 2024: 

1. Rimegepant (Biohaven Pharmaceutical) — designed to treat migraines.
   
   
2. OMG-157 (Novartis) — designed to treat multiple sclerosis.
   
   
3. Ozanimod (Celgene) — designed to treat multiple sclerosis.
    
4. Vadadustat (Akebia Therapeutics/Mitsubishi Tanabe Pharma America/ Otsuka Pharmaceutical) — designed to treat anemia caused by chronic kidney disease.
   
   
5. Valrox (BioMarin Pharmaceutical) — designed to treat hemophilia A.
   
   
6. Filgotinib (Gilead Sciences) — designed to treat rheumatoid arthritis.
   
   
7. Ryblesus (Novo Nordisk) — designed to treat Type 2 diabetes.
   
   
8. Inclisiran (The Medicines Company) — designed to treat high cholesterol.
   
   
9. Sacituzumab (Immunomedics) — designed to treat breast cancer.
   
   
10. Enhertu (Astrazeneca/ Daiichi Sankyo) — designed to treat breast cancer.
    
    
11. Liso-cel (Celgene) — designed to treat large B-cell lymphoma.